Patients with bladder cancer being treated with the immunotherapy agent, Keytruda, should not hesitate to call their oncology team if something does not feel right, an expert said. Patients with ...

Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...

Padcev (enfortumab vedotin-ejfv) is a brand-name infusion prescribed for urothelial cancer (a type of bladder cancer). As with other drugs, Padcev can cause side effects, such as rash and hair loss.

On Thursday, Merck & Co Inc (NYSE:MRK) announced discontinuing the Phase 3 KeyVibe-008 trial based on an independent Data Monitoring Committee (DMC) recommendation. The trial is evaluating the ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...